医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Promega ADCC Reporter Bioassay Named to The Scientist Top 10 Innovations for 2013

2013年12月03日 PM11:25
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

Representation of Promega ADCC Reporter Bioassay. Readout is luminescence signal from NFAT response element driving expression of firefly luciferase in the engineered Jurkat effector cell line. (Graphic: Business Wire)Representation of Promega ADCC Reporter Bioassay. Readout is luminescence signal from NFAT response element driving expression of firefly luciferase in the engineered Jurkat effector cell line. (Graphic: Business Wire)

View and Share Photo

Close Window


MADISON, Wis.

Promega Corporation is pleased to announce that The Scientist has named the ADCC Reporter Bioassay to its 2013 Top 10 Innovations. The ADCC Reporter Bioassay is a surrogate assay for evaluating antibody-dependent, cell-mediated cytotoxicity (ADCC) of therapeutic mAbs, and it exhibits greatly reduced variability and is easier to perform than classic ADCC assays. ADCC is the primary mechanism of action of many mAb therapeutic drugs.

Representation of Promega ADCC Reporter Bioassay. Readout is luminescence signal from NFAT response  ...

Representation of Promega ADCC Reporter Bioassay. Readout is luminescence signal from NFAT response element driving expression of firefly luciferase in the engineered Jurkat effector cell line. (Graphic: Business Wire)

This innovation is transforming biologics drug development by allowing the biotech industry to more easily and reproducibly characterize mAb therapeutic drugs during manufacturing and lot release, as well as in earlier drug development stages such as clonal selection of antibodies.

The new ADCC Reporter Bioassay is available in kits with cells provided in frozen, thaw-and-use format, plus components to perform a homogeneous bioassay in a single day. The product replaces variable natural killer effector cells, typically primary in origin, with engineered effector cells that use a reporter gene readout approach. The effector cells, and control target cells, are ready to use without need for cell culture propagation.

The assay possesses all of the hallmarks of an optimal bioassay – excellent linearity, specificity, repeatability, precision and accuracy – and therefore can be used for potency lot release, stability indicating and antibody screening applications. Furthermore, the bioassay is sensitive enough to assess the impact of post-translational modifications, such as glycosylation and fucosylation, an area of intense exploration, on the potency of mAbs.

To learn more about this enabling technology, or view a webinar, please see www.promega.com/adcc.

Promega is pleased to be named in The Scientist’s Top 10 Innovations for the second year in a row following the 2012 recognition of NanoLuc® Luciferase.

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 2,500 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 15 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20131203005156/en/

CONTACT

Promega Corporation
Penny Patterson, (608) 274-4330
Sr.
Director, Communications
penny.patterson@promega.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表